Evoq Remedies Share Price Today | Stock Price & Evoq Remedies Share Screener
Track the current Evoq Remedies share price and stock price live with TickJournal's free stock screener. Check EVOQ 52-week high low for the annual price range and momentum. Use the Evoq Remedies stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Evoq Remedies opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Evoq Remedies Share Price Chart
Track the current stock price of Evoq Remedies with an interactive chart. Analyse EVOQ share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Evoq Remedies stock quote in one place.
Evoq Remedies Company Profile - Fundamental Screener
Screen Evoq Remedies company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for EVOQ shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Commercial Services sector and the Trading & Distributors industry, and it trades under ISIN INE0JVD01011.
Company Details
Classification
Identifiers and Leadership
Evoq Remedies Balance Sheet Screener
Screen EVOQ balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2025, total assets were ₹50, up from ₹37 in 2024.
Latest statistics put total assets at ₹50 and shareholder funds at ₹45, with a leverage ratio of 0.06.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
Assets |
|||||||
| Total Assets | 50 | 37 | 35 | 33 | 8 | 6 | 2 |
| Current Assets | 50 | 37 | 35 | 33 | 8 | 6 | 2 |
| Fixed Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Liabilities |
|||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
|||||||
| Total Equity | 45 | 25 | 25 | 23 | 1 | 0 | 0 |
| Share Capital | 25 | 14 | 14 | 14 | 0 | 0 | 0 |
| Reserves & Surplus | 20 | 12 | 11 | 10 | 1 | 0 | 0 |
Evoq Remedies Income Statement Screener - Profit & Revenue Analysis
Screen Evoq Remedies income statement and profit fundamentals. Analyze EVOQ quarterly results. Evoq Remedies reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹0 and net profit was ₹0.
In that period expenses were ₹0, interest cost ₹0 and tax ₹0. The next period listed, 2026-March, shows revenue of ₹26 and net profit of ₹0.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||
| Revenue | 0 | 26 | 14 | 6 | 26 | 17 | 10 | 9 | 3 |
| Expenses | 0 | 27 | 14 | 6 | 24 | 15 | 9 | 9 | 3 |
Operating Costs and Margins | |||||||||
| EBITDA | 0 | -1 | 0 | 1 | 2 | 2 | 1 | 0 | 0 |
| Operating Profit % | 0.00% | -6.00% | -19.00% | -40.00% | -18.00% | 9.00% | 10.00% | 0.00% | 1.00% |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||
| Profit Before Tax | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Net Profit | 0 | 0 | 0 | 1 | 2 | 1 | 1 | 0 | 0 |
| EPS | 0.00 | -0.10 | 0.04 | 0.33 | 1.19 | 0.70 | 715.00 | 0.00 | 0.16 |
Evoq Remedies Cash Flow Screener - Liquidity Fundamentals
Screen EVOQ cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities used ₹15.
Over the same period, investing activities provided ₹0 and financing activities provided ₹15.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March |
|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | |||||||
| Operating Activities | -15 | 5 | -4 | -26 | 0 | 0 | 0 |
| Investing Activities | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Financing and Net Cash | |||||||
| Financing Activities | 15 | -5 | 1 | 30 | 0 | 0 | 0 |
| Net Cash Flow | 0 | 0 | -3 | 3 | 0 | 0 | 0 |
Evoq Remedies Shareholding Pattern Screener
See Evoq Remedies shareholding pattern with promoter, FII, and DII holdings. Check Evoq Remedies promoter holding and ownership changes for EVOQ on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Mar, promoters held 0.02%, foreign institutions 0.00%, domestic institutions 0.00% and the public 94.57%, spread across 1,655 shareholders.
The shareholder count was 1,655 in 2026-Mar, compared with 1,723 in 2025-Mar.
| Item | 2026-Mar | 2025-Mar | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2023-Mar | 2023-Sept |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 0.02% | 11.21% | 11.21% | 20.53% | 11.21% | 11.21% | 73.53% | 73.53% |
Institutional Investors | ||||||||
| FII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| DII Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 94.57% | 84.74% | 83.89% | 73.38% | 85.57% | 85.75% | 25.21% | 24.91% |
| Other Holding | 5.41% | 4.05% | 4.90% | 6.09% | 3.21% | 3.04% | 1.26% | 1.56% |
| Shareholder Count | 1,655 | 1,723 | 1,679 | 1,672 | 1,588 | 1,577 | 707 | 727 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Evoq Remedies. Evoq Remedies dividend yield can be compared with peers and other stocks in the market.
Evoq Remedies Stock Index Membership - Nifty & Sensex
See which indices include Evoq Remedies stock. Check EVOQ index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
Complete Index List
Evoq Remedies Market Events Screener - Corporate Actions
Get Evoq Remedies corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Evoq Remedies stock events that may affect EVOQ share price, along with derivatives, futures and options activity and sector gainers.
9 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated May 30, 2026, with a record date of May 30, 2026.
It is followed by Quarterly Result Announcement dated October 10, 2025 and Annual General Meeting dated September 17, 2025.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-05-30 | 2026-05-30 | Quarterly Result Announcement | NA | -7.74% |
| 2025-10-10 | 2025-10-10 | Quarterly Result Announcement | NA | 14.87% |
| 2025-09-17 | 2025-09-17 | Annual General Meeting | NA | 7.43% |
| 2025-06-03 | 2025-06-03 | Extraordinary General Meeting | NA | 22.05% |
| 2025-04-10 | 2025-04-10 | Quarterly Result Announcement | NA | 9.77% |
| 2025-03-03 | 2025-03-03 | Quarterly Result Announcement | NA | 0.00% |
| 2024-09-28 | 2024-09-28 | Annual General Meeting | NA | -3.40% |
| 2024-02-28 | 2024-02-28 | Extraordinary General Meeting | NA | -1.84% |
| 2021-07-28 | 2021-07-28 | Change Of Name | NA | - |
Evoq Remedies Competitors Screener - Peer Stocks Comparison
Screen EVOQ competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Commercial Services sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Redington | 31,697 | 21.02 | 119,347 | 19.87% | 1,284 | 63.97 |
| MMTC | 8,514 | 18.94 | 181 | -31.28% | 387 | 29.89 |
| MSTC | 5,020 | 21.31 | 453 | 16.90% | 218 | 48.68 |
| Ravindra Energy | 2,961 | 49.20 | 543 | 107.17% | 84 | 44.09 |
| Vintage Coffee & Beverages | 2,660 | 33.36 | 553 | 76.98% | 72 | 60.13 |
| BN Agrochem | 2,026 | 126.86 | 874 | 137.94% | 34 | 35.76 |
| Creative Newtech | 1,648 | 21.91 | 2,718 | 50.85% | 70 | 46.00 |
| Elitecon International | 1,311 | 7.46 | 5,075 | 820.35% | 185 | 32.64 |
| TCC Concept | 1,190 | 17.29 | 0 | % | 0 | 48.69 |
| Pervasive Commodities | 1,049 | 44 | 43.56% | 0 | 100.00 |
Evoq Remedies Company Announcements - News & Reports Screener
Screen EVOQ latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated June 11, 2026.
The next most recent announcements are dated June 10, 2026 and May 30, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-06-11 | Corporate Insolvency Resolution Process (CIRP)-Admission of application by Tribunal | - |
| 2026-06-10 | Corporate Insolvency Resolution Process (CIRP)-Admission of application by Tribunal | - |
| 2026-05-30 | Integrated Filing (Finance) For The Half Year And Year Ended On 31St March 2026 | - |
| 2026-05-30 | Appointment Of M/S. Jay Pandya & Associates (FRN: S2024GJ963300) Company Secretaries Ahmedabad As Secretarial Auditor Of The Company For The Financial Year 2025-26. | - |
| 2026-05-30 | Submission Of Audited Financial Results For The Half Year And Year Ended On 31St March 2026 Along With AuditorS Report. | - |
| 2026-05-30 | Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Saturday 30Th May 2026 And Intimation Under Regulation 30 Of SEBI (LODR) Regulations 2015 | - |
| 2026-05-27 | Board Meeting Intimation for Intimation For Rescheduling Of Board Meeting From 27Th May 2026 To 30Th May 2026 | - |
| 2026-05-11 | Board Meeting Intimation for Intimation For Rescheduling Of Board Meeting From 14Th May 2026 To 27Th May 2026 | - |
| 2026-05-07 | Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Thursday 14Th May 2026 | - |
| 2026-04-30 | Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A | - |
| 2026-04-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-30 | Closure of Trading Window | - |
| 2026-01-06 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-10-24 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2025-10-23 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2025-10-23 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2025-10-10 | Integrated Filling (Finance) | - |
| 2025-10-10 | Financial Result For Half Year Ended On 30Th September 2025 | - |
| 2025-10-10 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2025-10-10 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
Frequently Asked Questions
How is the company valued right now?
The P/B ratio is 0.09. Market capitalisation stands at ₹3.63 Cr. The company operates in the Commercial Services sector, in the Trading & Distributors industry, so compare these ratios with its sector peers in the table above.
About This Data
Key statistics were last updated on October 6, 2026. This page covers 7 balance sheet periods, 9 income statement periods, 7 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.